Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Alcon, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 71 PAGES: 115

Alcon, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Alcon, Inc. - Product Pipeline Review - H2 2011” provides data on the Alcon, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Alcon, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Alcon, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Alcon, Inc. - Brief Alcon, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Alcon, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Alcon, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Alcon, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Alcon, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Alcon, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Alcon, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit c

More Info
									          Alcon, Inc. – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01697CDB

                                                                                                 Publication Date: NOV 2011




Alcon, Inc. – Product Pipeline Review – H2 2011                                             GMDHC01697CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Alcon, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 6
      List of Figures .................................................................................................................................................................................................... 7
Alcon, Inc. Snapshot................................................................................................................................................................................................. 8
      Alcon, Inc. Overview .......................................................................................................................................................................................... 8
      Key Information .................................................................................................................................................................................................. 8
      Key Facts ........................................................................................................................................................................................................... 8
Alcon, Inc. – Research and Development Overview ................................................................................................................................................. 9
      Key Therapeutic Areas ....................................................................................................................................................................................... 9
Alcon, Inc. – Pipeline Review ..................................................................................................................................................................................12
      Pipeline Products by Stage of Development ......................................................................................................................................................12
      Alcon, Inc. – Pipeline Products Glance ..............................................................................................................................................................13
      Alcon, Inc. – Late Stage Pipeline.......................................................................................................................................................................13
            Registration Filed Products/Combination Treatment Modalities...................................................................................................................13
            Phase III Products/Combination Treatment Modalities ................................................................................................................................14
      Alcon, Inc. Clinical Stage Pipeline Products ......................................................................................................................................................15
            Phase II Products/Combination Treatment Modalities .................................................................................................................................15
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................16
Alcon, Inc. – Drug Profiles .......................................................................................................................................................................................17
      AL-15469A + AL-6515.......................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
      AL-38583 ..........................................................................................................................................................................................................18
            Product Description ....................................................................................................................................................................................18
            Mechanism of Action...................................................................................................................................................................................18
            R&D Progress .............................................................................................................................................................................................18
      AL-39324 ..........................................................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      AL-43,546 .........................................................................................................................................................................................................20
            Product Description ....................................................................................................................................................................................20
            Mechanism of Action...................................................................................................................................................................................20
            R&D Progress .............................................................................................................................................................................................20
      AL-54478 ..........................................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      AL-59412C ........................................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      AL-8309B ..........................................................................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23




Alcon, Inc. – Product Pipeline Review – H2 2011                                                                                                             GMDHC01697CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Alcon, Inc. – Product Pipeline Review



           R&D Progress .............................................................................................................................................................................................23
     Brinzolamide + Brimonidine...............................................................................................................................................................................24
           Product Description ....................................................................................................................................................................................24
           Mechanism of Action...................................................................................................................................................................................24
           R&D Progress .............................................................................................................................................................................................24
     DuoTrav ............................................................................................................................................................................................................25
           Product Description ....................................................................................................................................................................................25
           Mechanism of Action...................................................................................................................................................................................25
           R&D Progress .............................................................................................................................................................................................25
     Durezol .............................................................................................................................................................................................................26
           Product Description ....................................................................................................................................................................................26
           Mechanism of Action...................................................................................................................................................................................26
           R&D Progress .............................................................................................................................................................................................26
     ESBA1008 ........................................................................................................................................................................................................27
           Product Description ....................................................................................................................................................................................27
           Mechanism of Action...................................................................................................................................................................................27
           R&D Progress .............................................................................................................................................................................................27
     FID 114657 .......................................................................................................................................................................................................28
           Product Description ....................................................................................................................................................................................28
           Mechanism of Action...................................................................................................................................................................................28
           R&D Progress .............................................................................................................................................................................................28
     Lucentis + AL-78898A .......................................................................................................................................................................................29
           Product Description ....................................................................................................................................................................................29
           Mechanism of Action...................................................................................................................................................................................29
           R&D Progress .............................................................................................................................................................................................29
     Nevanac............................................................................................................................................................................................................30
           Product Description ....................................................................................................................................................................................30
           Mechanism of Action...................................................................................................................................................................................30
           R&D Progress .............................................................................................................................................................................................30
     POT-4 ...............................................................................................................................................................................................................31
           Product Description ....................................................................................................................................................................................31
           Mechanism of Action...................................................................................................................................................................................31
           R&D Progress .............................................................................................................................................................................................31
     Zyclorin .............................................................................................................................................................................................................32
           Product Description ....................................................................................................................................................................................32
           Mechanism of Action...................................................................................................................................................................................32
           R&D Progress .............................................................................................................................................................................................32
Alcon, Inc. – Pipeline Analysis .................................................................................................................................................................................33
     Alcon, Inc. – Pipeline Products by Therapeutic Class ........................................................................................................................................33
     Alcon, Inc. - Pipeline Products By Target ..........................................................................................................................................................35
     Alcon, Inc. – Pipeline Products by Route of Administration................................................................................................................................37
     Alcon, Inc. – Pipeline Products by Molecule Type .............................................................................................................................................38
Alcon, Inc. – Recent Pipeline Updates ....................................................................................................................................................................39
Alcon, Inc. - Dormant Projects .................................................................................................................................................................................43
Alcon, Inc. - Discontinued Pipeline Products............................................................................................................................................................44
     Discontinued Pipeline Product Profiles ..............................................................................................................................................................44
           Retaane ......................................................................................................................................................................................................44
           AL-39256 ....................................................................................................................................................................................................44




Alcon, Inc. – Product Pipeline Review – H2 2011                                                                                                            GMDHC01697CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(3)
Alcon, Inc. – Product Pipeline Review



Alcon, Inc. – Company Statement ...........................................................................................................................................................................45
Alcon, Inc. – Locations And Subsidiaries .................................................................................................................................................................48
     Head Office .......................................................................................................................................................................................................48
     Other Locations & Subsidiaries .........................................................................................................................................................................48
Alcon, Inc. - Key Manufacturing Facilities ................................................................................................................................................................55
Recent Developments .............................................................................................................................................................................................56
           Jul 31, 2007: Alcon's Treatment of Glaucoma and Ocular Hypertension, TRAVATANZ Solution, Approved in Japan.................................56
           Nov 30, 2007: Alcon Receives FDA Approval Of TRIESENCE Injectable Triamcinolone Suspension For Use In Eye Surgery....................56
           Sep 29, 2008: Potentia Pharmaceuticals Announces Positive Safety Data And Study Expansion In Phase I Trial For Lead Drug Candidate
           POT-4 .........................................................................................................................................................................................................56
           Mar 29, 2010: Alcon Completes Acquisition of Durezol from Sirion .............................................................................................................57
           Oct 27, 2008: Potentia Pharmaceuticals Announces To Present ASaP Clinical Trial Data During The AAO Annual Meeting ......................57
           Feb 27, 2008: Durezol receives NDA Acceptance and Priority Review From the FDA for in the Postoperative Ocular Inflammation
           Treatment. ..................................................................................................................................................................................................58
           Jul 26, 2006: Alcon's Eye Allergy Drug, PATANOL Ophthalmic Solution, Approved in Japan......................................................................58
           Jul 26, 2006: Alcon's Eye Allergy Drug, PATANOL Ophthalmic Solution, Approved in Japan......................................................................59
           Apr 26, 2004: Alcon Receives FDA Approval for a Supplemental List of Susceptible Pathogens for VIGAMOX Ophthalmic Solution..........59
           Sep 24, 2007: Alcon Receives FDA Decision On RETAANE Suspension For Wet AMD .............................................................................60
           Jun 24, 2008: Durezol recieves FDA approval for Treatment of Postoperative Ocular Inflammation and Pain. ............................................60
           May 24, 2005: Alcon Receives Approvable Letter From FDA For RETAANE Suspension ...........................................................................61
           Feb 24, 2006: Alcon Receives Positive Opinion For DuoTrav Eye Drops Solution From CHMP ..................................................................61
           Aug 23, 2005: Alcon's NEVANAC Suspension Receives FDA Approval For Treatment Of Pain And Inflammation Associated With Cataract
           Surgery .......................................................................................................................................................................................................62
           Jan 23, 2003: Alcon Develops New, Once-Daily Formulation of PATANOL Ophthalmic Solution For the Treatment of Ocular Allergies .....62
           Jan 23, 2003: FCB Patanol business has been awarded by Alcon .............................................................................................................63
           Jan 23, 2003: FCB Patanol business has been awarded by Alcon .....................................................
								
To top